Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Down-regulation of K-ras and H-ras in human brain gliomas.

Authors: Lymbouridou, Rena  Soufla, Giannoula  Chatzinikola, Anthoula M  Vakis, Antonios  Spandidos, Demetrios A 
Citation: Lymbouridou R, etal., Eur J Cancer. 2009 May;45(7):1294-303. doi: 10.1016/j.ejca.2008.12.028. Epub 2009 Jan 27.
Pubmed: (View Article at PubMed) PMID:19179066
DOI: Full-text: DOI:10.1016/j.ejca.2008.12.028

Ras genes, a class of nucleotide-binding proteins that regulate normal and transformed cell growth, have been scarcely investigated in human brain tumours. We evaluated the mutational, mRNA and protein expression profile of the ras genes in 21 glioblastomas multiforme (grade IV), four fibrillary astrocytoma (grade II), four anaplastic astrocytoma (grade III) and 15 normal specimens. K-, H- and N-ras transcript levels were determined by real-time RT-PCR and mutational status by PCR-restriction fragment length polymorphism (RFLP) and direct sequencing. p21 protein was evaluated by Western blot analysis. Two K-ras mutations were found in codons 16 and 26 in one pathological and one normal sample, respectively. Glioblastoma multiforme cases exhibited significantly lower K- and H-ras mRNA levels compared to controls (P < 10(-4)). K- and H-ras mRNA down-regulation was not associated with patient outcome or survival. K-ras was positively correlated with H-ras in glioblastomas (P = 0.005), but not in normal specimens. p21 protein was absent in all samples. Our findings provide evidence of K- and H-ras involvement in brain malignant transformation through transcriptional down-regulation, while N-ras seems to contribute less to brain carcinogenesis.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 13702872
Created: 2018-07-20
Species: All species
Last Modified: 2018-07-20
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.